Cogent Biosciences, Inc. (COGT) News
Follow Cogent Biosciences, Inc. (COGT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cogent Biosciences Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 02:04 PM UTC
L
Cogent Bio granted third FDA review for lead asset
Cogent Biosciences NASDAQ:COGT on Tuesday announced that the FDA has accepted its marketing application for its lead candidate, bezuclastinib, for a rare form of blood cancer, marking the third indication for which the t
REGULATION | Sep 15, 2026, 12:31 PM UTC
L
Cogent Biosciences, Inc. (NASDAQ:COGT) NDA Accepted for AdvSM; PDUFA Set for June 29, 2027
Cogent Biosciences, Inc. said the FDA accepted its NDA for bezuclastinib in Advanced Systemic Mastocytosis and set a PDUFA action date of June 29, 2027. FDA does not plan an advisory committee and noted no potential revi
REGULATION | Sep 15, 2026, 12:01 PM UTC
L
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSMPDUFA target action date set for June 29, 2027WALTHAM
REGULATION | Sep 15, 2026, 12:01 PM UTC
L
COGT - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
COGT - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
REGULATION | Sep 15, 2026, 12:01 PM UTC
L
Cogent Biosciences files SEC disclosure on Hovione supply agreement
Cogent Biosciences disclosed an agreement with Hovione in an SEC filing, covering entry into a commercial supply agreement effective Sept. 1, 2026.
REGULATION | Sep 02, 2026, 08:19 PM UTC
L
Cogent Biosciences signs commercial supply agreement with Hovione for bezuclastinib
Cogent Biosciences entered a Commercial Supply Agreement with Hovione to manufacture bezuclastinib spray-dried dispersion and tablets. Deal uses rolling quarterly forecasts with a binding near-term portion and minimum, d
EQUITY | Sep 02, 2026, 08:13 PM UTC
L
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis
Cogent Biosciences, Inc. (Nasdaq: COGT ), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application (NDA) to the U.S. Fo
REGULATION | Jun 30, 2026, 12:04 PM UTC